Eyestem plans to further investigate these promising results in a phase 2 study in India and the US. The company previously announced it had completed the first round of dosing in its trial in August ...

(RTTNews) - Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009 ...

The information and technology gauge Nifty IT index jumped three percent in the opening session on April 8, tracking positive global cues as the risk-off mode ebbed, giving way to a bullish market ...

“The remarkable results from Cohort 3 of the ongoing Phase 2 trial reinforce the potential of SLS009 to transform outcomes for these heavily pretreated AML patients,” said Angelos Stergiou, MD, ScD ...

Credit: Getty Images In a phase 3 clinical trial ... and safety of inebilizumab in adult patients with gMG who tested positive for either acetylcholine receptor (AChR+) or muscle-specific kinase ...

The 25-year-old still has some ways to go before returning to the big leagues, but he is making very positive strides ... Gibson was able to go up-and-down three times and he is nearing a debut ...

a differentiated protocol that is aligned with the positive subpopulation data and informed by feedback from discussions with the FDA is expected to guide the design of the planned Phase 3 trial.

As a once-daily oral therapy, based on the data from this study, ICP-488 will be “a valuable treatment option for moderate to severe plaque psoriasis” if phase 3 data confirm these findings ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...

Among them, three patients experienced over ... completion of Clinical Study Report (CSR) for Phase 1/Dose Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma(BCC), ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...